NASDAQ:CNTA Centessa Pharmaceuticals Q4 2024 Earnings Report $13.75 -0.04 (-0.29%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$13.74 -0.01 (-0.04%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Centessa Pharmaceuticals EPS ResultsActual EPS-$0.34Consensus EPS -$0.38Beat/MissBeat by +$0.04One Year Ago EPSN/ACentessa Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACentessa Pharmaceuticals Announcement DetailsQuarterQ4 2024Date3/24/2025TimeBefore Market OpensConference Call DateMonday, March 24, 2025Conference Call Time7:00AM ETUpcoming EarningsCentessa Pharmaceuticals' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Centessa Pharmaceuticals Earnings HeadlinesRelative Strength Alert For Centessa PharmaceuticalsApril 3, 2025 | nasdaq.comMorgan Stanley Remains a Buy on Centessa Pharmaceuticals (CNTA)April 2, 2025 | markets.businessinsider.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.April 29, 2025 | Paradigm Press (Ad)Piper Sandler Initiates Coverage of Centessa Pharmaceuticals plc - Depositary Receipt () (CNTA) with Overweight RecommendationMarch 31, 2025 | msn.comNotable Two Hundred Day Moving Average Cross - CNTAMarch 28, 2025 | nasdaq.comCentessa reports Q4 EPS (84c), consensus (35c)March 25, 2025 | markets.businessinsider.comSee More Centessa Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Centessa Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Centessa Pharmaceuticals and other key companies, straight to your email. Email Address About Centessa PharmaceuticalsCentessa Pharmaceuticals (NASDAQ:CNTA), a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.View Centessa Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alphabet Rebounds After Strong Earnings and Buyback AnnouncementMarkets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Upcoming Earnings QUALCOMM (4/30/2025)Automatic Data Processing (4/30/2025)Microsoft (4/30/2025)Meta Platforms (4/30/2025)KLA (4/30/2025)Equinix (4/30/2025)Lloyds Banking Group (4/30/2025)Itaú Unibanco (4/30/2025)Banco Santander (4/30/2025)Equinor ASA (4/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
